CN111479566B - 用于治疗病毒和细菌感染的新mek抑制剂 - Google Patents

用于治疗病毒和细菌感染的新mek抑制剂 Download PDF

Info

Publication number
CN111479566B
CN111479566B CN201880081184.5A CN201880081184A CN111479566B CN 111479566 B CN111479566 B CN 111479566B CN 201880081184 A CN201880081184 A CN 201880081184A CN 111479566 B CN111479566 B CN 111479566B
Authority
CN
China
Prior art keywords
use according
infection
pharmaceutically acceptable
virus
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880081184.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN111479566A (zh
Inventor
S·路德维格
O·普兰兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Westfaelische Wilhelms Universitaet Muenster
Original Assignee
Westfaelische Wilhelms Universitaet Muenster
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Westfaelische Wilhelms Universitaet Muenster filed Critical Westfaelische Wilhelms Universitaet Muenster
Priority to CN202410133936.5A priority Critical patent/CN118141795A/zh
Publication of CN111479566A publication Critical patent/CN111479566A/zh
Application granted granted Critical
Publication of CN111479566B publication Critical patent/CN111479566B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201880081184.5A 2017-10-17 2018-10-17 用于治疗病毒和细菌感染的新mek抑制剂 Active CN111479566B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410133936.5A CN118141795A (zh) 2017-10-17 2018-10-17 用于治疗病毒和细菌感染的新mek抑制剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
LULU100487 2017-10-17
LU100487 2017-10-17
PCT/EP2018/078335 WO2019076947A1 (en) 2017-10-17 2018-10-17 NEW MEK INHIBITOR FOR THE TREATMENT OF VIRAL AND BACTERIAL INFECTIONS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410133936.5A Division CN118141795A (zh) 2017-10-17 2018-10-17 用于治疗病毒和细菌感染的新mek抑制剂

Publications (2)

Publication Number Publication Date
CN111479566A CN111479566A (zh) 2020-07-31
CN111479566B true CN111479566B (zh) 2024-05-07

Family

ID=60484427

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880081184.5A Active CN111479566B (zh) 2017-10-17 2018-10-17 用于治疗病毒和细菌感染的新mek抑制剂
CN202410133936.5A Pending CN118141795A (zh) 2017-10-17 2018-10-17 用于治疗病毒和细菌感染的新mek抑制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410133936.5A Pending CN118141795A (zh) 2017-10-17 2018-10-17 用于治疗病毒和细菌感染的新mek抑制剂

Country Status (21)

Country Link
US (2) US11903917B2 (OSRAM)
EP (2) EP3973960B1 (OSRAM)
JP (3) JP7227967B2 (OSRAM)
KR (1) KR102848960B1 (OSRAM)
CN (2) CN111479566B (OSRAM)
AU (2) AU2018351475A1 (OSRAM)
BR (1) BR112020007442A2 (OSRAM)
CA (1) CA3078424A1 (OSRAM)
CY (1) CY1124507T1 (OSRAM)
DK (1) DK3697405T3 (OSRAM)
EA (1) EA202090693A1 (OSRAM)
ES (2) ES3041322T3 (OSRAM)
HR (1) HRP20211252T1 (OSRAM)
HU (1) HUE055738T2 (OSRAM)
LT (1) LT3697405T (OSRAM)
MX (2) MX2020003473A (OSRAM)
PL (1) PL3697405T3 (OSRAM)
PT (1) PT3697405T (OSRAM)
SI (1) SI3697405T1 (OSRAM)
WO (1) WO2019076947A1 (OSRAM)
ZA (1) ZA202002069B (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11903917B2 (en) * 2017-10-17 2024-02-20 Atriva Therapeutics Gmbh MEK-inhibitor for the treatment of viral and bacterial infections
LU101183B1 (en) * 2019-04-16 2020-10-16 Atriva Therapeutics Gmbh Novel mek-inhibitor for the treatment of viral and bacterial infections
CA3149588A1 (en) 2019-08-27 2021-03-04 Oliver Planz Combinations of mek inhibitors with cap-dependent endonuclease inhibitors
BR112022005896A2 (pt) * 2019-10-08 2022-06-28 Atriva Therapeutics Gmbh Inibidores da mek para o tratamento de infecções causadas por hantavírus
ES2995196T3 (en) * 2020-05-20 2025-02-07 Atriva Therapeutics Gmbh Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm
CN112957361B (zh) * 2021-03-24 2022-07-29 中国科学院武汉病毒研究所 曲美替尼在制备抗沙粒病毒的抗病毒制剂中的应用
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019113A2 (en) * 2010-08-05 2012-02-09 Case Western Reserve University Inhibitors of erk for developmental disorders of neuronal connectivity
WO2014056894A1 (en) * 2012-10-08 2014-04-17 Westfaelische Wilhelms-Universitaet Muenster Mek inhibitors in the treatment of virus diseases
WO2015173788A1 (en) * 2014-05-16 2015-11-19 Westfaelische Wilhelms-Universitaet Muenster Novel anti-infective strategy against influenza virus and s. aureus coinfections

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6310060B1 (en) * 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
EP1140067A1 (en) * 1999-01-07 2001-10-10 Warner-Lambert Company Antiviral method using mek inhibitors
TR200200082T2 (tr) * 1999-07-16 2002-04-22 Warner-Lambert Company MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi.
DE10017480A1 (de) 2000-04-07 2001-10-11 Transmit Technologietransfer Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren
CA2473545A1 (en) 2002-01-23 2003-07-31 Warner-Lambert Company Llc N-(4-substituted phenyl)-anthranilic acid hydroxamate esters
DE10300222A1 (de) * 2003-01-03 2004-07-15 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Verwendung von Wirksubstanzen zur Prophylaxe und/oder Therapie von Viruserkrankungen
JP2007055983A (ja) * 2005-08-26 2007-03-08 Tokyo Univ Of Science 細胞内に侵入した病原性細菌に起因する疾患の予防・改善剤
US11903917B2 (en) * 2017-10-17 2024-02-20 Atriva Therapeutics Gmbh MEK-inhibitor for the treatment of viral and bacterial infections
BR112022005896A2 (pt) 2019-10-08 2022-06-28 Atriva Therapeutics Gmbh Inibidores da mek para o tratamento de infecções causadas por hantavírus
ES2995196T3 (en) 2020-05-20 2025-02-07 Atriva Therapeutics Gmbh Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019113A2 (en) * 2010-08-05 2012-02-09 Case Western Reserve University Inhibitors of erk for developmental disorders of neuronal connectivity
CN103221043A (zh) * 2010-08-05 2013-07-24 卡斯西部储备大学 用于治疗神经元连接发育障碍的erk抑制剂
WO2014056894A1 (en) * 2012-10-08 2014-04-17 Westfaelische Wilhelms-Universitaet Muenster Mek inhibitors in the treatment of virus diseases
CN105101999A (zh) * 2012-10-08 2015-11-25 S·普莱施卡 用在病毒性疾病的治疗中的mek抑制剂
WO2015173788A1 (en) * 2014-05-16 2015-11-19 Westfaelische Wilhelms-Universitaet Muenster Novel anti-infective strategy against influenza virus and s. aureus coinfections
CN107073123A (zh) * 2014-05-16 2017-08-18 归属疗法有限公司 抗流感病毒和金黄色葡萄球菌合并感染的新型抗感染策略

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Beyond the MEK-pocket: Can current MEK kinase inhibitors be utilized to synthesize novel type III NCKIs Does the MEK-pocket exist in kinases other than MEK;Haile Tecle 等;《Bioorganic & Medicinal Chemistry Letters》;20081031;第226-229页 *
Haile Tecle 等.Beyond the MEK-pocket: Can current MEK kinase inhibitors be utilized to synthesize novel type III NCKIs Does the MEK-pocket exist in kinases other than MEK.《Bioorganic & Medicinal Chemistry Letters》.2008, *
The MEK-inhibitor CI-1040 displays a broad anti-influenza virus activity in vitro and provides a prolonged treatment window compared to standard of care in vivo;Emanuel Haasbach 等;Antiviral Res;20170630;第178-184页 *
抗流感病毒药物宿主靶点的研究进展;马琳琳;蒋建东;李玉环;;药学学报;20141212(第12期);第11-18页 *

Also Published As

Publication number Publication date
MX2020003473A (es) 2020-10-01
US11903917B2 (en) 2024-02-20
MX2022016066A (es) 2023-02-02
SI3697405T1 (sl) 2021-11-30
BR112020007442A2 (pt) 2020-10-27
HRP20211252T1 (hr) 2021-11-12
EP3973960B1 (en) 2025-09-03
JP2025031917A (ja) 2025-03-07
JP7227967B2 (ja) 2023-02-22
CY1124507T1 (el) 2022-07-22
KR20200072499A (ko) 2020-06-22
US20240245637A1 (en) 2024-07-25
CN111479566A (zh) 2020-07-31
AU2018351475A1 (en) 2020-04-30
EP3697405B1 (en) 2021-07-14
ES3041322T3 (en) 2025-11-11
LT3697405T (lt) 2021-10-25
AU2024205853A1 (en) 2024-09-05
CA3078424A1 (en) 2019-04-25
ZA202002069B (en) 2021-10-27
EP3973960A1 (en) 2022-03-30
EA202090693A1 (ru) 2020-10-19
JP7618276B2 (ja) 2025-01-21
PL3697405T3 (pl) 2021-12-13
US20200289445A1 (en) 2020-09-17
DK3697405T3 (da) 2021-08-23
KR102848960B1 (ko) 2025-08-21
JP2023058631A (ja) 2023-04-25
WO2019076947A1 (en) 2019-04-25
ES2883639T3 (es) 2021-12-09
HUE055738T2 (hu) 2021-12-28
CN118141795A (zh) 2024-06-07
EP3697405A1 (en) 2020-08-26
PT3697405T (pt) 2021-08-27
EP3973960C0 (en) 2025-09-03
JP2020537659A (ja) 2020-12-24

Similar Documents

Publication Publication Date Title
CN111479566B (zh) 用于治疗病毒和细菌感染的新mek抑制剂
US11135263B2 (en) Novel-anti-infective strategy against influenza virus and S. aureus coinfections
US12350244B2 (en) MEK-inhibitor for the treatment of viral and bacterial infections
AU2020258002B2 (en) Novel MEK-inhibitor for the treatment of viral and bacterial infections
EA042391B1 (ru) Новый ингибитор mek для лечения вирусных и бактериальных инфекций
HK40029715B (en) Novel mek-inhibitor for the treatment of viral and bacterial infections
HK40029715A (en) Novel mek-inhibitor for the treatment of viral and bacterial infections
EA047137B1 (ru) Новый ингибитор mek для лечения вирусных и бактериальных инфекций

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant